catheter technology News
-
Symple Surgical Inc. Completes Series A Common Stock Financing
Menlo Park, California – October 31, 2013 – In a tough investment climate for medical device companies 1 , Symple Surgical Inc. announced today that it has completed a Series A Common Stock financing, totaling approximately $1.9 million to fund its novel microwave catheter technology platform. Daniel J. Kasprzyk, founder of Machine Solutions Inc. and entrepreneur with multiple device ...
-
Q’Apel Medical announces FDA clearance for Walrus Balloon Guide Catheter.
In the neurovascular space where speed, reliability, and performance are so critical to patient outcomes, physicians and patients demand that innovative technologies are best-in-class. The walrus BGC, with its 087 ID, marks a big step forward in balloon guide catheter technology and for stroke patients worldwide. “I expect its introduction will be welcomed by neurovascular physicians ...
-
Q’Apel Medical announces first-in-human case with Wahoo.
Q’Apel Medical, a neurovascular medical device company, today announced it successfully completed the first-in-human case with the Wahoo access catheter, utilizing the next-generation SelectFlex technology. The procedure was performed by Raymond Turner, M.D., at Prisma Health in Greenville, South Carolina. The Wahoo access catheter contains proprietary SelectFlex variable stiffness ...
-
King Nelson joins Q’Apel Medical as CEO
Q'Apel Medical announced today that industry veteran King Nelson is joining the company as CEO. Nelson brings more than three decades of experience as a medical device executive and has extensive background in new product development, marketing and commercialization. Prior to Q’Apel, Nelson served as President and CEO of Uptake Medical, Kerberos Solutions and VenPro Cardiovascular. The ...
-
Neurescue Announces Appointment of Medtronic Veteran Mette-Marie Harild to Company’s Board of Directors
COPENHAGEN, Denmark--(BUSINESS WIRE)--Neurescue, a clinical-stage medical device company bringing to market the world’s first computer-aided balloon catheter for aortic occlusion, today announced that medical device industry veteran Mette-Marie Harild has been appointed to the Neurescue board of directors. Most recently the regional vice president of Medtronic’s largest sub-region in ...
By Neurescue
-
Adagio Medical Announces Successful First-In-Human Cases of Pulsed Field Cryoablation for Treatment of Atrial Fibrillation
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced first-in-human cases of pulsed field cryoablation (PFCA) for the treatment of atrial fibrillation (AF). The cases were performed at Medicover Hospital, Warsaw, Poland by Dr. Pawel Derejko, Head of the Department of Cardiology at Medicover and ...
-
Okami Medical Announces Closing Of $7.2M Series D Financing
Aliso Viejo, CA- June 24, 2020 – Okami Medical Inc., announced today the close of a Series D financing totaling $7.2 million. The financing was led by U.S. Venture Partners and was joined by members of Okami’s board of directors and medical device industry veterans. The financing provides Okami, the second portfolio company of medical device incubator Inceptus Medical LLC, with ...
-
Adagio Medical Reports 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Presents Recent Developments of Pulsed Field Cryoablation Technology
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the results of its CryoCure-2 ultra-low temperature cryoablation (ULTC) prospective multi-center study in patients with AF at the 2021 Heart Rhythm Society Annual Meeting. The late-breaking clinical trials presentation was delivered by Dr. Tom De ...
-
Imperative Care Announces First Patient Enrolled in the Imperative Trial Evaluating the Zoom 88 Large Distal Platform for the Treatment of Ischemic Stroke
Imperative Care, Inc. announced today that the first patient has been enrolled in the Imperative Trial. This prospective, multi-center clinical trial is the first study designed to evaluate the clinical benefits of direct aspiration for the treatment of ischemic stroke with the Zoom 88 Large Distal Platform, which is currently FDA cleared for neurovascular access. Additionally, the trial will ...
-
Adagio Medical Announces First-In-Human Use and Initiation of Multi-Center Study of Ultra-Low Temperature Cryoablation for Treatment of Recurrent Ventricular Tachycardia, Opening New Possibilities for High-Risk Patients
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, Associate Director, Cardiovascular Center ...
-
Infraredx, a Nipro Company, Announces Enrollment of First Patient in EXPANSE PTCA study.
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE ...
-
Adagio Medical Announces Publication of Cryocure-2 Data Reporting 85% Freedom from AF at 12 Months After a Single Ablation Procedure in Patients with Persistent Atrial Fibrillation and Discusses Current Status of iCLAS Cryoablation System
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), announced the publication of the results of its Cryocure-2 ultra-low temperature cryoablation (ULTC) study in patients with AF in the Journal of American College of Cardiology (JACC), Clinical Electrophysiology.1 The study prospectively enrolled 79 patients at ...
-
Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. This PFA system – comprising a sheath, generator and catheters – is intended to ablate ...
-
Landmark Lipid-Rich Plaque (LRP) Study Results Demonstrate the Ability to Accurately Identify Patients and Plaques at Risk for Major Coronary Events
Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, presented late-breaking clinical trial results for its landmark Lipid-Rich Plaque (LRP) Study today at the 30th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. Cardiovascular disease remains the number one cause of death globally, ...
-
Volta Medical’s VX1 AI software for use in atrial fibrillation mapping now FDA cleared
Volta Medical, a pioneering French-based HealthTech startup is pleased to announce that it has obtained FDA clearance for its revolutionary VX1 AI (artificial intelligence) software. This is the first FDA clearance for an AI based tool in interventional cardiac electrophysiology. VX1 is a machine and deep learning-based algorithm designed to assist operators in the real-time manual annotation of ...
-
Volta Medical raises 23 million Euros to revolutionize persistent AF ablation
Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 23 million Euros. The financing round was led by Gilde Healthcare with participation of existing shareholder Pasteur Mutualité. The new capital will allow the company to establish its revolutionary ...
-
Q’Apel Medical Welcomes Jodie Fam, Vice President and General Manager, International
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Jodie Fam as Vice President and General Manager, International. Jodie will be responsible for the leadership and development of International Sales for Q’Apel. Jodie brings more than 20 ...
-
Q’Apel Medical Welcomes Thomas Berryman, Chief Financial Officer
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Thomas Berryman as Chief Financial Officer. Tom has extensive experience in bringing venture funded medical technology companies from initial startup through product commercialization, revenue ...
-
Kardium performs first cases with the Globe® Positioning System
VANCOUVER, British Columbia – Kardium is pleased to announce the first clinical use of the Globe Positioning System (GPS™) – the new 3D mapping and navigation feature of its flagship product, the Globe® Mapping and Ablation System. The Globe System is the most complete solution for the treatment of atrial fibrillation (AF) – the world’s most common heart rhythm ...
By Kardium Inc.
-
First Patients in the U.S. Enrolled in Biosense Webster Clinical Study To Evaluate VARIPULSE™ Catheter for Atrial Fibrillation
Johnson & Johnson MedTech* announced today that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S. to evaluate the safety and effectiveness of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you